Pantoprazole is a proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs as they inhibit prostaglandin synthesis required for mucus production, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome.
Gastroesophageal reflux disease (GERD)
Zollinger-Ellison Syndrome
Peptic ulcer
Erosive Esophagitis (EE)
Bacterial Infection Due to Helicobacter Pylori
Pantoprazole is benzimidazole derivatives. It inhibits gastric acid secretion for a longer duration. H(+)/K(+)-ATPase of the proton pump secrets hydrochloric acid (HCl) secretion into the gastric lumen, expressed in high quantities by the parietal cells of the stomach. Parietal cell membrane contains ATPase an enzyme that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid). The active form then makes disulfide bonds with important cysteines on the gastric acid pump, inhibiting its function. The enzyme is inactivated, inhibiting gastric acid secretion.
Pantoprazole is well orally absorbed with bioavailability of 77%. The volume of distribution is 11.0-23.6 L and is 98% bound to plasma protein. It is mainly metabolised in liver by CYP enzymes. About 71% is excreted in urine and 18% is excreted in feces. The half-life of pantoprazole is 1 hour.
Common side effect includes:
Headache
Diarrhea
Stomach pain
Nausea or vomiting
Gas
Dizziness
Joint pain
People with osteoporosis as it can increase the risk.
People with low blood magnesium
| Pantaprazole | 40 mg |